论文部分内容阅读
目的探讨孟鲁司特、布地奈德治疗病毒感染婴幼儿喘息的临床疗效及预后。方法将54例病毒感染的喘息患儿分为观察组与对照组,两组给以常规综合治疗,对照组26例加用地塞米松0.2mg/kg静脉点滴,治疗组28例在常规综合治疗基础上口服孟鲁司特钠4mg/次,每日顿服,疗程3个月,布地奈德混悬液0.5mg/次,雾化吸入,每日2次,疗程5～7d,观察两组临床症状、体征恢复情况及患儿住院天数,对所有病例随访3个月,观察患儿再次发生喘息的情况。结果治疗组咳嗽、喘息、哮鸣音消失时间、患儿住院天数与对照组比较差异有统计学意义,随访3个月,治疗组患儿喘息发生率低于对照组。结论病毒感染的婴幼儿喘息应用孟鲁司特、布地奈德联合治疗疗效确切,能够降低喘息的复发率。
Objective To investigate the clinical efficacy and prognosis of montelukast and budesonide in the treatment of wheezing infants with viral infection. Methods 54 cases of asthmatic children with viral infection were divided into observation group and control group. The two groups were treated with conventional comprehensive treatment. In control group, 26 cases were treated with 0.2 mg / kg dexamethasone intravenously. The treatment group (28 cases) On the oral montelukast sodium 4mg / times daily service, treatment for 3 months, budesonide suspension 0.5mg / times, inhalation, 2 times a day, the course of treatment 5 ~ 7d, the two groups of clinical Symptoms, signs of recovery and hospitalization days, all cases were followed up for 3 months to observe the resumption of wheezing in children. Results The treatment group cough, wheezing, wheeze disappear time, hospitalization days compared with the control group, the difference was statistically significant, 3 months follow-up, the treatment group children with wheezing incidence was lower than the control group. Conclusion The combination of montelukast and budesonide in infants and young children with viral infection has a definite curative effect and can reduce the recurrence rate of wheezing.